Zymeworks is awaiting key regulatory decisions for zanidatamab, with potential EU and China approvals following. Read more ...

Pandemic exposed EU states to worrying pharma supply shortages, leading to widespread calls for more home-manufactured pharma ...

U.S. stocks reacted positively following the Federal Open Market Committee's announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately ...

Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

The autumn wave of coronavirus is sweeping across Germany. Those affected mainly suffer from coughs, colds, sore throats and ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN).

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...